Immatics (IMTX) Income from Continuing Operations (2019 - 2025)
Immatics' (IMTX) quarterly Income from Continuing Operations came in at 46184590.49 in Q4 2025, down 228.9% year-on-year from 35831072.36 in Q4 2024, and up 22.23% quarter-over-quarter from 59386829.59 in Q3 2025.
Immatics (IMTX) Income from Continuing Operations (2019 - 2025) Analysis & Trends
Immatics has disclosed Income from Continuing Operations across 7 years of filings, most recently posting 46184590.49 for Q4 2025.
- Income from Continuing Operations for Q4 2025 came in at 46184590.49, down 228.9% year-over-year; the trailing twelve-month figure through Dec 2025 was 229391557.84 (down 1631.15% YoY), and the FY2025 annual result was 226442407.73, down 1492.47% from the prior year.
- Income from Continuing Operations came in at 46184590.49 for Q4 2025 at Immatics, up from 59386829.59 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 96141693.63 in Q1 2022 to a low of 81897283.43 in Q2 2025.
- The 5-year median for Income from Continuing Operations is 23996855.1 (2023), against an average of 18209114.54.
- Across the five-year window, Income from Continuing Operations jumped 449.38% in 2022 and plunged 9127.64% in 2025, its largest moves.
- Immatics' Income from Continuing Operations stood at 19203840.36 in 2021, then soared by 111.78% to 2261888.41 in 2022, then tumbled by 1343.81% to 28133676.74 in 2023, then jumped by 227.36% to 35831072.36 in 2024, then slumped by 228.9% to 46184590.49 in 2025.
- The last three Income from Continuing Operations figures came in at 46184590.49 (Q4 2025), 59386829.59 (Q3 2025), and 81897283.43 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Immatics | 14.67 Bn | 14.67 Bn | - | -46.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -46.18 Mn |
| Sep 30, 2025 | -59.39 Mn |
| Jun 30, 2025 | -81.90 Mn |
| Mar 31, 2025 | -41.92 Mn |
| Dec 31, 2024 | 35.83 Mn |
| Sep 30, 2024 | 657,833.48 |
| Jun 30, 2024 | -19.07 Mn |
| Mar 31, 2024 | -2.43 Mn |
| Dec 31, 2023 | -28.13 Mn |
| Sep 30, 2023 | -28.84 Mn |
| Jun 30, 2023 | -26.80 Mn |
| Mar 31, 2023 | -21.20 Mn |
| Dec 31, 2022 | 2.26 Mn |
| Sep 30, 2022 | -19.98 Mn |
| Jun 30, 2022 | -12.47 Mn |
| Mar 31, 2022 | 96.14 Mn |
| Dec 31, 2021 | -19.20 Mn |
| Sep 30, 2021 | -32.08 Mn |
| Jun 30, 2021 | -31.95 Mn |
| Mar 31, 2021 | -27.52 Mn |